(33) demonstrated that the absence of IL-1RI in CMO mice significantly shortened the disease onset time and reduced the degree of bone lesions, indicating that controlling the number of IL-1R1 could be a potential therapeutic direction for CMO caused by PSTPIP2 deficiency. This evidence concerns the gene PSTPIP2 and chronic recurrent multifocal osteomyelitis.